The rapid test for COVID-19 antibodies is not as accurate as previously thought


The kit used by medical staff in the UK and the EU involves drawing a small amount of blood from the finger or vein to detect antibodies, particularly specific proteins that respond to infection. While it’s fast – results appear in less than 20 minutes – it doesn’t cause significant discomfort and no specialized lab equipment is needed, the test isn’t as accurate, experts warn.

The AbC-19 rapid tests were developed so that workers in the British and European medical system could soon discover the mass of people in communities who hold SARS-CoV-2 antibodies. In this regard, the UK government has ordered one million test kits, which represents 75 million pounds, about 100 million dollars, notes

The order was initiated following the positive results of the study funded by the British Rapid Test Consortium, an entity representing commercial companies, including Abingdon Health and Omega Diagnostics, which created AbC-19.

The study, led by researchers from the University of Ulster in Northern Ireland, has been published but has not yet received a final evaluation. The test is based on the correct identification of a negative result, without the risk of displaying a false negative. As for the false positive result, the test cannot accurately determine whether the affected person is positive or false positive.

Research from Ulster revealed a test sensitivity of 97.7%, which means the ability to correctly detect a positive result.

An independent study by Irish experts focusing on the AbC-19 rapid test suggests different conclusions and leads scientists to draw attention to the infection rate scenario.

More information about this study at

If you like this article, we expect you to join the community of readers on our Facebook page, via a Like below:


Source link